What is Glasdegib?

Glasdegib is a new type of drug that is a Hedgehog signaling pathway inhibitor and is mainly used for the combined treatment of newly diagnosed acute myeloid leukemia (AML) adult patients aged ≥75 years. The drug works by binding to and inhibiting the Smoothened (Smo) protein, a transmembrane protein involved in Hedgehog signaling. Research shows that disruption of the Hedgehog signaling pathway can effectively interfere with the development and survival of cancer stem cells, thereby fighting certain types of cancer.

In the clinical trialBRIGHT 1003, a total of 115 newly diagnosed AML patients were randomly divided into two groups to receive treatment with Glasgib combined with low-dose cytarabine (LDAC) or LDAC alone. The results showed that the median overall survival of patients who received the combination treatment with Glasgib was 8.3 months, while the median overall survival of patients who received LDAC alone was 4.3 months. This significant difference showed that patients treated with Glasgib combined with LDAC had a 54% reduction in the risk of death, demonstrating the potential of daresimod to improve survival in elderly AML patients.

Glasgib is an oral medication recommended once daily in combination with low-dose cytarabine. During use, be aware that the label contains a warning about embryo-fetal toxicity. In addition, some common side effects were reported during clinical trials, with incidence rates of ≥20%. Major side effects include anemia, fatigue, bleeding, fever, neutropenia, musculoskeletal pain, nausea, edema, thrombocytopenia, dyspnea, decreased appetite, dysgeusia, mucositis, constipation, and rash.

In summary, Glasgib, as a newHedgehog pathway inhibitor, provides a new treatment option for elderly patients with acute myeloid leukemia, and its clinical application prospects deserve attention. However, when using it, it is necessary to fully evaluate its potential side effects based on the patient's specific situation to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/history/daurismo.html